

(43) International Publication Date
27 June 2013 (27.06.2013)(10) International Publication Number
WO 2013/093849 A1

(51) International Patent Classification:

C07D 413/14 (2006.01) A61P 19/02 (2006.01)
C07D 498/04 (2006.01) A61P 37/08 (2006.01)
A61K 31/536 (2006.01) A61P 35/00 (2006.01)
A61K 31/5365 (2006.01) A61P 33/06 (2006.01)

(21) International Application Number:

PCT/IB2012/057554

(22) International Filing Date:

20 December 2012 (20.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/579,231 22 December 2011 (22.12.2011) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
CH-4056 Basel (CH).

(72) Inventors: **CARAVATTI, Giorgio**; Novartis Pharma AG,
Werk Klybeck, Postfach, CH-4002 Basel (CH).
CHAMOIN, Sylvie; Novartis Pharma AG, Postfach, CH-
4002 Basel (CH). **FURET, Pascal**; Novartis Pharma AG,
Werk Klybeck, Postfach, CH-4002 Basel (CH). **HÖ-**
GENAUER, Klemens; Novartis Pharma AG, Werk Kly-
beck, Postfach, CH-4002 Basel (CH). **HURTH, Konstan-**
ze; Novartis Pharma AG, Werk Klybeck, Postfach, CH-
4002 Basel (CH). **KALIS, Christoph**; Novartis Pharma
AG, Postfach, CH-4002 Basel (CH). **KAMMERTOENS,**
Karen; Novartis Pharma AG, Werk Klybeck, Postfach,
CH-4002 Basel (CH). **LEWIS, Ian**; Novartis Pharma AG,
Postfach, CH-4002 Basel (CH). **MOEBITZ, Henrik**; No-
vartis Pharma AG, Werk Klybeck, Postfach, CH-4002
Basel (CH). **SMITH, Alexander Baxter**; Novartis Pharma
AG, Postfach, CH-4002 Basel (CH). **SOLDERMANN,**

Nicolas; Novartis Pharma AG, Werk Klybeck, Postfach,
CH-4002 Basel (CH). **WOLF, Romain**; Novartis Pharma
AG, Postfach, CH-4002 Basel (CH). **ZECRI, Frédéric**;
Novartis Institutes for BioMedical Research, Inc., 100
Technology Square, Cambridge, Massachusetts 02139
(US).

(74) Agent: **VON SPRECHER, Georg**; Novartis Pharma AG,
Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES



(I)

(57) Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R¹, R⁵, R⁷ and R³⁰ are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*